Russian authorities have tightened CFC compliance requirements for pharmaceutical-sector tax residents. Review your exposure now. Make an enquiry.
Alert: Russian development affecting CFC rules and Russian tax residents in the pharmaceuticals sector Effective: April 2027
The Federal Tax Service has intensified scrutiny of controlled foreign company (CFC) compliance among Russian tax residents operating in the pharmaceuticals sector. Recent audit cycles indicate that FTS inspectors are applying a stricter documentary standard when reviewing CFC notifications and profit calculations for companies with pharmaceutical distribution, manufacturing, or licensing structures — a development that in-house counsel at foreign-owned Russian entities should treat as requiring immediate internal review.
Russian tax residents — including individuals and legal entities that control foreign companies — are required under the CFC regime established by Russian tax legislation to notify the FTS of their controlled foreign companies and, where applicable, include undistributed CFC profits in their Russian taxable base. In the pharmaceuticals sector, this regime intersects with a regulatory environment already subject to close government attention: pricing controls, state procurement requirements, and licensing obligations administered by the Ministry of Health and FAS Russia all generate documentary trails that FTS auditors are now cross-referencing against CFC filings. Companies that have relied on standard CFC exemptions — including the active business exemption applicable to foreign operating companies — should verify that their factual basis for those exemptions remains robust under current FTS interpretive positions.
The risk of failing to satisfy FTS documentation requests is not theoretical. In recent enforcement activity, companies in regulated sectors that could not substantiate the active business character of their foreign subsidiaries faced CFC profit inclusions and associated penalties. For Russian subsidiaries of international pharmaceutical groups, this creates direct exposure at the local entity level — not only for the Russian individual shareholders or senior management who may separately qualify as controlling persons.
Recommended action:
Audit your current CFC notification and profit calculation positions for any pharmaceutical-related foreign entities held directly or indirectly by Russian tax residents connected to your Russian operations.Review documentary support for any active business or other CFC profit exemptions claimed in the past three financial years — FTS inspectors are requesting underlying operational evidence, not solely financial statements.Engage Russian tax counsel before any FTS information request arrives; a voluntary compliance review conducted in advance of an audit typically provides materially stronger positioning.
For advice on CFC rules and Russian tax residents in the pharmaceuticals sector, or to discuss how recent FTS enforcement trends affect your Russian structure, contact our Tax Controversy practice: info@vetrovpartners.com |
Further context is available on our Tax Controversy practice page and in our analysis of how Russian courts approach CFC rules and Russian tax residents.
— Kristina Kornouhova Senior Lawyer, Practice Lead — Tax & Antitrust, Vetrov & Partners vetrovpartners.com/kornouhova/
This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.
Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.
Make an enquiry